Covered recipient · General Payments record
MIGUEL ESTEBAN TREVINO
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$4,245.42
118 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,805.78 | 110 |
| Travel and Lodging | $1,439.64 | 8 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| JAZZ PHARMACEUTICALS INC. | $1,460.84 | 11 |
| Alnylam Pharmaceuticals Inc. | $1,095.94 | 10 |
| Lilly USA, LLC | $277.89 | 19 |
| ABBVIE INC. | $220.60 | 13 |
| Biohaven Pharmaceutical Holding Company Ltd. | $189.15 | 14 |
| Amgen Inc. | $138.55 | 7 |
| Novo Nordisk Inc | $109.76 | 6 |
| TerSera Therapeutics LLC | $98.62 | 3 |
| GlaxoSmithKline, LLC. | $89.09 | 4 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $81.60 | 3 |
| AstraZeneca Pharmaceuticals LP | $72.12 | 5 |
| Janssen Pharmaceuticals, Inc | $51.60 | 3 |
| Novartis Pharmaceuticals Corporation | $50.41 | 3 |
| Takeda Pharmaceuticals U.S.A., Inc. | $43.10 | 2 |
| Lucid Diagnostics Inc. | $41.42 | 2 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $38.69 | 2 |
| PFIZER INC. | $36.48 | 2 |
| Inogen, Inc. | $21.53 | 1 |
| Abbott Laboratories | $19.85 | 1 |
| Mylan Specialty L.P. | $18.56 | 1 |
| IDORSIA PHARMACEUTICALS US INC | $17.65 | 1 |
| Currax Pharmaceuticals LLC | $16.62 | 1 |
| CSL Behring | $16.42 | 1 |
| Teva Pharmaceuticals USA, Inc. | $14.03 | 1 |
| IMPEL PHARMACEUTICALS INC. | $13.19 | 1 |
| Kowa Pharmaceuticals America, Inc. | $11.71 | 1 |
Page 3 of 3; records 101–118 of 118 matching records. This page contains 18 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MIGUEL ESTEBAN TREVINO
NPI 1760411029 · CMS profile ID 33939
Allopathic & Osteopathic Physicians / Internal Medicine
CLEARWATER, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–118 of 118 matching records. This page contains 18 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1760411029?year=2022&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MIGUEL ESTEBAN TREVINO, NPI 1760411029, CMS profile ID 33939. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–118 of 118 matching records. This page contains 18 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1760411029?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). MIGUEL ESTEBAN TREVINO, NPI 1760411029, CMS profile ID 33939. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–118 of 118 matching records. This page contains 18 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1760411029?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- MIGUEL ESTEBAN TREVINO, NPI 1760411029, CMS profile ID 33939, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–118 of 118 matching records. This page contains 18 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1760411029?year=2022&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
118 matching records · $4,245.42 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–118 of 118.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.87 | 02/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 959490686 | CMS |
| Lilly USA, LLC | $18.59 | 02/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918249815 | CMS |
| Lilly USA, LLC | $15.92 | 02/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918204979 | CMS |
| Novo Nordisk Inc | $20.20 | 02/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 899153765 | CMS |
| ABBVIE INC. | $14.13 | 02/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892549703 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $34.19 | 02/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887406819 | CMS |
| GlaxoSmithKline, LLC. | $27.67 | 02/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944883449 | CMS |
| Janssen Pharmaceuticals, Inc | $13.82 | 02/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885912563 | CMS |
| IMPEL PHARMACEUTICALS INC. | $13.19 | 02/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 962324239 | CMS |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.48 | 02/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923757121 | CMS |
| Lilly USA, LLC | $14.55 | 02/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918204977 | CMS |
| ABBVIE INC. | $19.03 | 01/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892549701 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.97 | 01/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915757844 | CMS |
| ABBVIE INC. | $23.18 | 01/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892549699 | CMS |
| Novo Nordisk Inc | $15.74 | 01/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 898586233 | CMS |
| Biohaven Pharmaceutical Holding Company Ltd. | $9.25 | 01/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923757119 | CMS |
| Amgen Inc. | $18.73 | 01/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939904311 | CMS |
| Kowa Pharmaceuticals America, Inc. | $11.71 | 01/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 900380079 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,245.37 | 9 |
| PY2025 | Principal investigator | $901,206.15 | 342 |
| PY2024 | Recipient | $1,781.08 | 12 |
| PY2024 | Principal investigator | $1,014,674.74 | 833 |
| PY2023 | Recipient | $2,126.57 | 4 |
| PY2023 | Principal investigator | $1,679,100.89 | 1,197 |
| PY2022 | Recipient | $2,021.52 | 9 |
| PY2022 | Principal investigator | $1,303,551.21 | 1,145 |
| PY2021 | Recipient | $195.16 | 1 |
| PY2021 | Principal investigator | $847,944.00 | 418 |
| PY2020 | Recipient | $350.00 | 1 |
| PY2020 | Principal investigator | $961,001.47 | 479 |
| PY2019 | Recipient | $864.30 | 10 |
| PY2019 | Principal investigator | $1,348,913.08 | 357 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
351 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $5,520.00 | 12/31/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism | No dispute reported | 06/30/2026 | 1202532470 |
| Principal investigator 1 | PFIZER INC. | $617.50 | 12/31/2025 | Non-covered Recipient Entity Innovative Research of West Florida Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228749199 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298438 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298440 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298442 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298444 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298446 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298448 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298450 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298452 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298454 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298456 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298458 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298460 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298462 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298464 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298466 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298468 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298470 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298472 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298474 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298476 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298478 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298480 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298482 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298484 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298488 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298490 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298493 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298496 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298498 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298500 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298502 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298504 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298506 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298508 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298510 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298512 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298514 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298516 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298518 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298520 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298522 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298524 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298526 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298528 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298530 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298532 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298534 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298536 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298538 |
| Principal investigator 1 | Seqirus USA Inc | $555.10 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298540 |
| Principal investigator 1 | Seqirus USA Inc | $274.30 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298542 |
| Principal investigator 1 | Seqirus USA Inc | $274.30 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298544 |
| Principal investigator 1 | Seqirus USA Inc | $274.30 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298630 |
| Principal investigator 1 | Seqirus USA Inc | $555.10 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298634 |
| Principal investigator 1 | Seqirus USA Inc | $748.80 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298636 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298644 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298648 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298650 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298652 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298654 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298656 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298658 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298660 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298662 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298664 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298666 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298668 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298670 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298672 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298674 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298676 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298678 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298680 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298682 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298684 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298686 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298688 |
| Principal investigator 1 | Seqirus USA Inc | $2,294.50 | 12/26/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298690 |
| Principal investigator 1 | Seqirus USA Inc | $274.30 | 12/19/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298628 |
| Principal investigator 1 | Seqirus USA Inc | $555.10 | 12/19/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298632 |
| Principal investigator 1 | Seqirus USA Inc | $748.80 | 12/19/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298638 |
| Principal investigator 1 | Seqirus USA Inc | $748.80 | 12/19/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298692 |
| Principal investigator 1 | Seqirus USA Inc | $274.30 | 12/19/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298694 |
| Principal investigator 1 | Seqirus USA Inc | $274.30 | 12/19/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298696 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $11,200.00 | 12/12/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO) | No dispute reported | 06/30/2026 | 1185555137 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $938.60 | 12/10/2025 | Non-covered Recipient Entity Innovative Research of West Florida | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215510741 |
| Principal investigator 1 | ABBVIE INC. | $3,394.30 | 12/05/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202529288 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 12/04/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184269323 |
| Principal investigator 1 | PFIZER INC. | $666.25 | 11/29/2025 | Non-covered Recipient Entity Innovative Research of West Florida Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228728691 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $85.80 | 11/07/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184259121 |
| Principal investigator 1 | ABBVIE INC. | $728.00 | 11/06/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202523477 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $194.00 | 11/06/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510709 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $67.00 | 11/06/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510713 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.75 | 11/06/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510717 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $63.00 | 11/06/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510722 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $160.50 | 11/06/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510726 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $61.00 | 11/06/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510730 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $31.00 | 11/06/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510733 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $54.00 | 11/06/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510737 |
| Principal investigator 1 | ABBVIE INC. | $16,357.90 | 11/05/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202522727 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,409.00 | 10/31/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210851 |
| Principal investigator 1 | PFIZER INC. | $308.75 | 10/31/2025 | Non-covered Recipient Entity Innovative Research of West Florida Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228741248 |
| Principal investigator 1 | Seqirus USA Inc | $4,274.00 | 10/31/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1250810539 |
| Principal investigator 1 | Seqirus USA Inc | $1,174.50 | 10/31/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1250810543 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,724.20 | 10/22/2025 | Non-covered Recipient Entity Innovative Research of West Florida | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215510744 |
| Principal investigator 1 | Seqirus USA Inc | $1,880.00 | 10/22/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298642 |
| Principal investigator 1 | Seqirus USA Inc | $6,575.00 | 10/22/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298646 |
| Principal investigator 1 | ABBVIE INC. | $1,384.50 | 10/21/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202517619 |
| Principal investigator 1 | ABBVIE INC. | $1,384.50 | 10/21/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202517627 |
| Principal investigator 1 | ABBVIE INC. | $2,256.80 | 10/21/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202517629 |
| Principal investigator 1 | ABBVIE INC. | $2,256.80 | 10/21/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202517631 |
| Principal investigator 1 | PFIZER INC. | $308.75 | 10/15/2025 | Non-covered Recipient Entity Innovative Research of West Florida Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228719819 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $168.65 | 10/14/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | No dispute reported | 06/30/2026 | 1192167922 |
| Principal investigator 1 | ABBVIE INC. | $15,382.90 | 10/09/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202515767 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $928.97 | 10/03/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184244745 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,976.00 | 10/03/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184244747 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,693.00 | 10/03/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184244749 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,005.30 | 10/02/2025 | Non-covered Recipient Entity INNOVATIVE RES OF W FL INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192167933 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,260.00 | 09/25/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210792 |
| Principal investigator 1 | PFIZER INC. | $1,604.85 | 09/24/2025 | Non-covered Recipient Entity Innovative Research of West Florida Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228759070 |
| Principal investigator 1 | ABBVIE INC. | $2,256.80 | 09/18/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202511530 |
| Principal investigator 1 | ABBVIE INC. | $3,340.00 | 09/18/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202511532 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,000.00 | 09/17/2025 | Non-covered Recipient Entity Innovative Research of West Florida | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215510536 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,739.00 | 09/17/2025 | Non-covered Recipient Entity Innovative Research of West Florida | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215510654 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,835.00 | 09/15/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210628 |
| Principal investigator 1 | Seqirus USA Inc | $111.30 | 09/15/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298624 |
| Principal investigator 1 | Seqirus USA Inc | $177.19 | 09/15/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298626 |
| Principal investigator 1 | Seqirus USA Inc | $1,420.20 | 09/15/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185298640 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $303.00 | 09/12/2025 | Non-covered Recipient Entity Innovative Research of West Florida | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215510641 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $388.00 | 09/12/2025 | Non-covered Recipient Entity Innovative Research of West Florida | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215510646 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $144.00 | 09/12/2025 | Non-covered Recipient Entity Innovative Research of West Florida | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215510650 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $928.97 | 09/12/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184236626 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,755.00 | 09/11/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210890 |
| Principal investigator 1 | PFIZER INC. | $3,379.03 | 09/09/2025 | Non-covered Recipient Entity Innovative Research of West Florida Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228752879 |
| Principal investigator 1 | ABBVIE INC. | $23,076.30 | 09/04/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202509592 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,388.24 | 09/03/2025 | Non-covered Recipient Entity INNOVATIVE RES OF W FL INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192168657 |
| Principal investigator 1 | ABBVIE INC. | $956.14 | 08/28/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202506507 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,050.00 | 08/28/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | No dispute reported | 06/30/2026 | 1192164740 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,050.00 | 08/28/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | No dispute reported | 06/30/2026 | 1192164750 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $957.70 | 08/26/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184230409 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,487.00 | 08/25/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210533 |
| Principal investigator 1 | ABBVIE INC. | $2,030.60 | 08/20/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202505271 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $150.00 | 08/20/2025 | Non-covered Recipient Entity Innovative Research of West Florida | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215510531 |
| Principal investigator 1 | Janssen Research & Development, LLC | $791.00 | 08/19/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210128 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 08/19/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210746 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,457.00 | 08/19/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210922 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,407.00 | 08/15/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510566 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $61.00 | 08/15/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510570 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $181.00 | 08/15/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510573 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $63.00 | 08/15/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510577 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $54.00 | 08/15/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510580 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $194.00 | 08/15/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510585 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $160.50 | 08/15/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510589 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $259.00 | 08/15/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510593 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $67.00 | 08/15/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510598 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $31.00 | 08/15/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510603 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $67.00 | 08/15/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510704 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $957.70 | 08/14/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184228355 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $288.00 | 08/13/2025 | Non-covered Recipient Entity Innovative Research of West Florida | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215510658 |
| Principal investigator 1 | ABBVIE INC. | $17,134.00 | 08/06/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202503507 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,216.00 | 08/06/2025 | Non-covered Recipient Entity INNOVATIVE RES OF W FL INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192167925 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,461.20 | 08/04/2025 | Non-covered Recipient Entity INNOVATIVE RES OF W FL INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192164763 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,998.00 | 07/31/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210201 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,762.00 | 07/31/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210303 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,009.00 | 07/31/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210457 |
| Principal investigator 1 | Janssen Research & Development, LLC | $267.00 | 07/31/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210496 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,750.00 | 07/31/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210658 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,562.00 | 07/31/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210683 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,368.76 | 07/31/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184222876 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,902.00 | 07/28/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210258 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $281.68 | 07/28/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226120446 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $31.50 | 07/25/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510607 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $194.00 | 07/25/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510612 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $53.50 | 07/25/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510617 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $67.00 | 07/25/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510621 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $67.00 | 07/25/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510699 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,986.00 | 07/23/2025 | Non-covered Recipient Entity INNOVATIVE RES OF W FL INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192167906 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $928.97 | 07/22/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184217849 |
| Principal investigator 1 | Seqirus USA Inc | $1,000.00 | 07/18/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298622 |
| Principal investigator 1 | ABBVIE INC. | $436.80 | 07/17/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202498660 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,791.64 | 07/17/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184217164 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,476.25 | 07/16/2025 | Non-covered Recipient Entity Innovative Research of West Florida | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215510528 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $7,730.15 | 07/14/2025 | Non-covered Recipient Entity Innovative Research of West Florida | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215510637 |
| Principal investigator 1 | Janssen Research & Development, LLC | $788.00 | 07/14/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210930 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,300.00 | 07/14/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226120434 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,368.76 | 07/10/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184214422 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,000.00 | 07/07/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510625 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,001.00 | 07/07/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510629 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $675.00 | 07/07/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510633 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $300.00 | 07/07/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226120440 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,334.46 | 07/04/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184212925 |
| Principal investigator 1 | ABBVIE INC. | $14,612.00 | 07/02/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202495427 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $63.00 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510681 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $181.00 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510685 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $61.00 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510689 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $67.00 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510693 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $350.00 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510799 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $516.00 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510804 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $61.00 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510807 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $181.00 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510811 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $54.00 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510815 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $194.00 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510819 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $160.50 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510822 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $259.00 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510826 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $31.00 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510830 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $67.00 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510834 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $63.00 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510839 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $31.50 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510842 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $53.50 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510846 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $31,326.20 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510850 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $67.00 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510854 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $31.00 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510858 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $67.00 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510862 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $61.00 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510866 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $54.00 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510870 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $194.00 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510874 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $67.00 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510878 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $181.00 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510882 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $259.00 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510886 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $160.50 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510890 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $194.00 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510894 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $54.00 | 07/02/2025 | Non-covered Recipient Entity Innovative Research of West Florida | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510898 |
| Principal investigator 1 | Seqirus USA Inc | $675.00 | 07/02/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298620 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,000.00 | 06/25/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210113 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,014.08 | 06/24/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184210698 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $873.00 | 06/20/2025 | Non-covered Recipient Entity INNOVATIVE RES OF W FL INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192164758 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,415.41 | 06/19/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184209251 |
| Principal investigator 1 | Janssen Research & Development, LLC | $39,616.00 | 06/13/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210560 |
| Principal investigator 1 | ABBVIE INC. | $1,644.50 | 06/12/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202491011 |
| Principal investigator 1 | ABBVIE INC. | $2,953.60 | 06/12/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202491013 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $957.70 | 06/12/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184206337 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,404.14 | 06/05/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184204237 |
| Principal investigator 1 | ABBVIE INC. | $35,971.00 | 06/03/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202487371 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,368.76 | 05/28/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184198911 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,368.76 | 05/22/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184197661 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,724.20 | 05/21/2025 | Non-covered Recipient Entity Innovative Research of West Florida | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215510795 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,511.90 | 05/21/2025 | Non-covered Recipient Entity INNOVATIVE RES OF W FL INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192164744 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,403.00 | 05/20/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210090 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $468.00 | 05/16/2025 | Non-covered Recipient Entity INNOVATIVE RES OF W FL INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192167910 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,725.34 | 05/08/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184193773 |
| Principal investigator 1 | ABBVIE INC. | $11,251.50 | 05/07/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202483793 |
| Principal investigator 1 | ABBVIE INC. | $2,075.00 | 04/30/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202480645 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,568.00 | 04/30/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210266 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,028.16 | 04/28/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184190741 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,101.20 | 04/23/2025 | Non-covered Recipient Entity INNOVATIVE RES OF W FL INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192167918 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $15,319.56 | 04/22/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184185269 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $12,450.40 | 04/18/2025 | Non-covered Recipient Entity Innovative Research of West Florida | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215510786 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,896.95 | 04/18/2025 | Non-covered Recipient Entity Innovative Research of West Florida | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215510791 |
| Principal investigator 1 | Janssen Research & Development, LLC | $408.00 | 04/17/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175211020 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,808.28 | 04/15/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184183386 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,339.12 | 04/10/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | No dispute reported | 06/30/2026 | 1192164772 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,246.00 | 04/10/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210065 |
| Principal investigator 1 | Janssen Research & Development, LLC | $267.00 | 04/10/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210769 |
| Principal investigator 1 | Seqirus USA Inc | $870.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298546 |
| Principal investigator 1 | Seqirus USA Inc | $415.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298548 |
| Principal investigator 1 | Seqirus USA Inc | $870.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298550 |
| Principal investigator 1 | Seqirus USA Inc | $870.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298552 |
| Principal investigator 1 | Seqirus USA Inc | $415.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298554 |
| Principal investigator 1 | Seqirus USA Inc | $415.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298556 |
| Principal investigator 1 | Seqirus USA Inc | $415.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298558 |
| Principal investigator 1 | Seqirus USA Inc | $415.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298560 |
| Principal investigator 1 | Seqirus USA Inc | $415.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298562 |
| Principal investigator 1 | Seqirus USA Inc | $415.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298564 |
| Principal investigator 1 | Seqirus USA Inc | $415.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298566 |
| Principal investigator 1 | Seqirus USA Inc | $415.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298568 |
| Principal investigator 1 | Seqirus USA Inc | $870.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298570 |
| Principal investigator 1 | Seqirus USA Inc | $415.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298572 |
| Principal investigator 1 | Seqirus USA Inc | $415.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298574 |
| Principal investigator 1 | Seqirus USA Inc | $415.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298576 |
| Principal investigator 1 | Seqirus USA Inc | $415.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298578 |
| Principal investigator 1 | Seqirus USA Inc | $415.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298580 |
| Principal investigator 1 | Seqirus USA Inc | $415.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298582 |
| Principal investigator 1 | Seqirus USA Inc | $415.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298584 |
| Principal investigator 1 | Seqirus USA Inc | $415.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298586 |
| Principal investigator 1 | Seqirus USA Inc | $415.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298588 |
| Principal investigator 1 | Seqirus USA Inc | $415.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298590 |
| Principal investigator 1 | Seqirus USA Inc | $870.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298592 |
| Principal investigator 1 | Seqirus USA Inc | $415.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298594 |
| Principal investigator 1 | Seqirus USA Inc | $415.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298596 |
| Principal investigator 1 | Seqirus USA Inc | $415.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298598 |
| Principal investigator 1 | Seqirus USA Inc | $415.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298600 |
| Principal investigator 1 | Seqirus USA Inc | $415.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298602 |
| Principal investigator 1 | Seqirus USA Inc | $415.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298604 |
| Principal investigator 1 | Seqirus USA Inc | $415.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298606 |
| Principal investigator 1 | Seqirus USA Inc | $870.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298608 |
| Principal investigator 1 | Seqirus USA Inc | $870.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298610 |
| Principal investigator 1 | Seqirus USA Inc | $870.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298612 |
| Principal investigator 1 | Seqirus USA Inc | $870.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298614 |
| Principal investigator 1 | Seqirus USA Inc | $870.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298616 |
| Principal investigator 1 | Seqirus USA Inc | $870.00 | 04/09/2025 | Non-covered Recipient Entity Innovative Research Of West Florida | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185298618 |
| Principal investigator 1 | Janssen Research & Development, LLC | $280.00 | 04/04/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210634 |
| Principal investigator 1 | ABBVIE INC. | $6,643.00 | 04/03/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202474275 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $14,737.80 | 04/02/2025 | Non-covered Recipient Entity INNOVATIVE RES OF W FL INC | A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T | No dispute reported | 06/30/2026 | 1192164201 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $928.97 | 04/01/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184180746 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,884.00 | 03/24/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210319 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $20.57 | 03/21/2025 | Non-covered Recipient Entity Innovative Research of West Florida | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215510782 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $36.26 | 03/21/2025 | Covered Recipient Physician | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184123562 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $123.92 | 03/21/2025 | Covered Recipient Physician | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184123564 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $85.80 | 03/19/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184174478 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,030.00 | 03/14/2025 | Non-covered Recipient Entity Innovative Research of West Florida | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215510771 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $150.00 | 03/12/2025 | Non-covered Recipient Entity Innovative Research of West Florida | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215510768 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $600.00 | 03/12/2025 | Non-covered Recipient Entity Innovative Research of West Florida | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215510776 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10,574.26 | 03/11/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184170828 |
| Principal investigator 1 | ABBVIE INC. | $14,202.50 | 03/07/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202461577 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,339.12 | 03/07/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | No dispute reported | 06/30/2026 | 1192167930 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $288.15 | 03/07/2025 | Covered Recipient Physician | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184123552 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $66.99 | 03/07/2025 | Covered Recipient Physician | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184123554 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $33.71 | 03/07/2025 | Covered Recipient Physician | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184123556 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $64.99 | 03/07/2025 | Covered Recipient Physician | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184123558 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $32.99 | 03/07/2025 | Covered Recipient Physician | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184123560 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $149.99 | 03/06/2025 | Covered Recipient Physician | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184123550 |
| Principal investigator 1 | PFIZER INC. | $3,000.00 | 03/04/2025 | Non-covered Recipient Entity Innovative Research of West Florida Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228722882 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $741.00 | 03/04/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184156676 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $364.00 | 03/04/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184156678 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $3,388.41 | 03/03/2025 | Non-covered Recipient Entity Innovative Research of West Florida | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215510780 |
| Principal investigator 1 | PFIZER INC. | $10,065.00 | 03/01/2025 | Non-covered Recipient Entity Innovative Research of West Florida Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228782623 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/28/2025 | Non-covered Recipient Entity Innovative Research of West Florida, Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215518655 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/28/2025 | Non-covered Recipient Entity Innovative Research of West Florida, Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215518659 |
| Principal investigator 1 | ABBVIE INC. | $286.00 | 02/25/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202453768 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,880.90 | 02/25/2025 | Non-covered Recipient Entity INNOVATIVE RES OF W FL INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192164767 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $258.00 | 02/21/2025 | Non-covered Recipient Entity Innovative Research of West Florida | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215510764 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,240.00 | 02/18/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210780 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10,703.22 | 02/18/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184154272 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,000.00 | 02/18/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184154274 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,838.00 | 02/18/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184154276 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,041.00 | 02/18/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184154278 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,000.00 | 02/18/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184154280 |
| Principal investigator 1 | ABBVIE INC. | $614.16 | 02/13/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202451117 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,653.00 | 02/12/2025 | Non-covered Recipient Entity Innovative Research of West Florida | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215510749 |
| Principal investigator 1 | Genentech, Inc. | $829.00 | 02/10/2025 | Non-covered Recipient Entity Innovative Research of West Florida, Inc. | Phase 1c Selnoflast Proof of Concept | No dispute reported | 06/30/2026 | 1211614817 |
| Principal investigator 1 | ABBVIE INC. | $21,495.50 | 02/06/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202447577 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,250.00 | 02/06/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210225 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,458.00 | 02/06/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210867 |
| Principal investigator 1 | ABBVIE INC. | $897.00 | 02/05/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202444521 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2025 | Non-covered Recipient Entity Innovative Research of West Florida, Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215518647 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2025 | Non-covered Recipient Entity Innovative Research of West Florida, Inc. | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215518650 |
| Principal investigator 1 | ABBVIE INC. | $291.20 | 01/29/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202441796 |
| Principal investigator 1 | ABBVIE INC. | $276.90 | 01/29/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202441800 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $30,436.24 | 01/29/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185555131 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $198.00 | 01/24/2025 | Non-covered Recipient Entity Innovative Research of West Florida | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215510752 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,895.00 | 01/24/2025 | Non-covered Recipient Entity Innovative Research of West Florida | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215510756 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $846.00 | 01/24/2025 | Non-covered Recipient Entity Innovative Research of West Florida | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215510759 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,634.90 | 01/24/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185555135 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,643.60 | 01/24/2025 | Non-covered Recipient Entity INNOVATIVE RES OF W FL INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192164754 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $448.37 | 01/20/2025 | Covered Recipient Physician | A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome | No dispute reported | 06/30/2026 | 1184123548 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,295.00 | 01/16/2025 | Non-covered Recipient Entity Elias Rsrch Associates, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175210739 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $13,766.43 | 01/15/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA INC | a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older | No dispute reported | 06/30/2026 | 1185555133 |
| Principal investigator 1 | PFIZER INC. | $374.00 | 01/10/2025 | Non-covered Recipient Entity INNOVATIVE RESEARCH OF WEST FLORIDA | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228724628 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,695.00 | 01/08/2025 | Non-covered Recipient Entity INNOVATIVE RES OF W FL INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192167914 |